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ABSTRACT
Objectives: Pre-eclampsia (PE) affects many women worldwide and remains the leading cause of morbidity and mortal-
ity in neonatal and maternal settings. Abnormal expression of placental microRNAs (miRNAs) may be associated with PE.
Material and methods: This study was conducted to the relationship between IGF1 and the expression spectrum of miRNA 
in the placenta of preeclampsia patient. The expression of miRNA in placental tissue was compared between pre-eclampsia 
(n = 6) and normal pregnant women (n = 5) miRNA targets were studied by computer simulation and functional assays. The 
role of miRNA was verified in trophoblast cell lines by apoptosis assay and invasion assay. 
Results: There was a significant increase in miRNAs in the placenta of women with pre-eclampsia compared with patients 
with normal pregnancy. Luciferase assay confirmed direct regulation of miRNA.
Conclusions: The expression of IGF1 and miRNA was significantly increased in the placenta of patients with pre-eclampsia.
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INTRODUCTION
Preeclampsia (PE), eclampsia and gestational hyper-
tension are unique during pregnancy diseases, which falls 
within the category of gestational hypertension (hyperten-
sive disorders in pregnancy), morbidity [1–2]. It is about 10% 
in China, especially in preeclampsia. PE is mainly manifested 
within 20 weeks after pregnancy [3–4]. Hypertension, pro-
teinuria, can cause multiple organ dysfunction as well as 
functional failure in the whole body. This is leading to mater-
nal and the main cause of perinatal mortality has been the 
focus of pathological obstetric research, the pathogenesis 
is unknown. 
Because most preeclampsia conditions can quickly re-
lieve or even heal themselves after placental delivery, some 
scholars believe that the placenta is the root cause of its 
disease. In the process of embryo implantation and placenta 
formation, if various factors lead to trophoblastic dysfunc-
tion, it will cause uterine spiral artery recasting disorder, 
placental blood supply insufficientcy, which results in preec-
lampsia disease. With the gradual deepening of microRNA 
(miRNA) function research, more and more studies have 
confirmed that miRNA plays an important regulatory role 
in the development of PE. This provides molecular biology 
clues that reveal the pathogenesis of PE [5, 6]. 
MiRNAs in eukaryotic organisms, about 18-25 bases in 
length, by pairing with the target gene mRNA base to in-
duce the silent Complex (RISC) to degrade mRNA or inhibit 
its translation, thus achieving negative regulation of the 
expression level of the target gene at the post-transcription 
level. The discovery of MiRNAs is a milestone in the field of 
gene expression regulation, which regulates about 30% 
of human protein-coded genes, and is related to assorted 
physiological and pathological processes. For instance, em-
bryonic development, organ formation and the occurrence 
of diseases, through negative regulation of the level of target 
gene expression.
MATERIAL AND METHODS
Patient samples
All patients received written informed consent. The 
study was approved by the Institutional Review Board of 
the Second Affiliated Hospital of Nanchang University. Six 
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patients with pre-eclampsia placenta and 5 patients who 
underwent caesarean section were enrolled in our study. 
Patients who underwent caesarean section served as the 
control group. The 11 patients were used for microarray 
analysis of miRNAs. All of the patients were further evalu-
ated. Patients with pre-eclampsia were confirmed by clinical 
diagnosis by the professional doctor in our hospital. The pla-
centa tissues from patients were immediately snap-frozen 
in liquid nitrogen after abscission. The detailed information 
of samples were shown in Table 1 and Table 2.
Methods
Microarray analysis of miRNAs
The miRCURYTM LNA array (7th generation) (version 
18.0, Exiqon) includes 3,100 capture probes embodying the 
whole annotations in miRBase 18.0. the miRNAs of mice and 
rats, and the miRNAs of all viruses associated with them. 
Furthermore, the array covers the probes for miLlusTM hu-
man miRNAs [7]. 
Extraction of total RNA 
Total RNA of patients was extracted by using total RNA 
isolation kits (Invitrogen) and miRNeasy mini kits (QIAGEN) 
under the conditions recommended by the manufacturer. 
The purity of extracted RNA was determined by using the 
spectrophotometer (ND-1000, Nanodrop Technologies). 
In addition, we evaluated the RNA integrity by gel electro-
phoresis [8].
RNA labeling 
RNA labeling was performed by using the miR-
CURYTM Hy3TM / Hy5TM Power Labeling Kits (Exiqon, 
Vedbaek, Denmark). Furthermore, the sample (1 μg) was 
performed 3’-end-labeling by using a Hy3TM fluorescent 
label. We also mixed 2.0 μL of RNA in water with 1.0 μL 
LCIP buffer and CIP (Exiqon). The mixture was incubated 
at 37°C for 30 min and at 95°C for 5 min. In addition, we 
added labeling buffer (3.0 μL), labeling enzyme (2.0 μL), 
fluorescent label (Hy3TM) (1.5 μL), and DMSO (2.0 μL) into 
the mixture, which was incubated at 16°C for 1 h and at 
65°C for 15 min [9].
Array hybridization
The miRCURYTM LNA array (Section 18.0) (Exiqon) was 
used for array hybridization. Firstly, hybridization buffer 
[25 (mu)L] was added into the above sample [25 (mu)L]. 
Next, the mixture was incubated at 95 (deg.) C for 2 min 
in order to denaturate, followed by incubation at 4°C for 
2 min. After that, the mixture was hybridized to the micro-
array at 56 (deg.) C. for 16–20 h. Bay Hybridization Systems 
(Hybridization System — Nimblegen Systems, Inc., Madison, 
WI, USA) provided effective mixing and invariant incuba-
tion temperature. Finally, slides were prepared and washed 
three times with a wash buffer kit (Exiqon). After washed, 
slides were dried by centrifugation (400 rpm/min) for 5 min. 
Finally, slides were scanned using Axon GenePix 4000B mi-
croarray scanner (Axon Instruments, Foster City, CA) [10].
Array Information
Exiqon’s miRNA arrays feature Tm-standardized and 
LNATM enhanced capture probes, which have outstand-
ing specificity and sensitivity even for AT-rich miRNAs. They 
also have excellent repeatability. The correlation between 
arrays was 99%. The dynamic range was more than 5 orders 
of magnitude.
miRCURY LNA™ microRNA Array, 7th gen — hsa, 
mmu & rno 
The 7th generation miRNA array included 3100 capture 
probes, which covered the whole of miRNAs in humans, 
mice and rats annotated in miRBase 18.0, and viral miR-
Table 1. Sample Description
Sample Number Sample Name Group
1 34 T
2 42 T
3 86 T
4 90 T
5 95 T
6 114 T
7 32 N
8 63 N
9 50 N
10 71 N
11 81 N
Table 2. Hybridizations to be performed
Slide no. Hy3 Hy5
Slide 1 34
Slide 2 42
Slide 3 86
Slide 4 90
Slide 5 95
Slide 6 114
Slide 7 32
Slide 8 63
Slide 9 50
Slide 10 71
Slide 11 81
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NAs. Moreover, there were capture probes for miLlusTM 
human microRNAs in the array, which were proprietary 
microRNAs not found in miRBase [11].
Data analysis
The scanned image was imported into GenePix Pro 
6.0 software (Axon) for grid alignment and data extrac-
tion. The replicated miRNAs were averaged and the miRNAs 
more than 50 intensities were selected for calculation of 
normalization factors. The expressed data was normalized 
by using median normalization. Moreover, miRNAs, with 
obviously different expression, were discerned by using 
Volcano Plot filtration. MEV software (v4.6,TIGR) was used 
for hierarchical clustering. 
RESULTS
Low intensity filtering and data normalization
The scanned image was imputed into GenePix Pro 
6.0 software (Axon) to do grid alignment and to extract data. 
The repetitive miRNAs were average while miRNAs which 
were more than 50 intensities were chosen to calculate 
querynormalization. The median normalization was used 
to normalize the data of miRNA. The miRNAs were selected 
for differential expression. The following list represents only 
a subset of the overall results. The entire results can be found 
in the expression “expression matrix” in the miRNA expres-
sion profiling Data.xls file (Tab. 3).
miRNA purity
The box plot is an intuitive method in order to effec-
tively visualize the level of disaggregation of data sets. It is 
an effective way to compare the distribution of miRNAs. In 
addition, the log2 ratio distribution of each sample was 
basically identical (Left: data with non-normalized log2-ratio 
distribution; right: data with median normalized log2-ratio 
distribution) (Fig. 1).
Correlation Matrix and scatter plot
A scatter plot is a visualization that can be used to evalu-
ate the repetitiveness of chips. Its axis was the normalized 
signal value (scale scale) (Fig. 2). 
Differentially expressed miRNAs screening
Differentially expressed miRNAs with statistically signifi-
cant differences were identified. We performed Volcano Plot 
filtration on both groups in the experiment. The threshold, 
a fold change more than 1.5 and a P value less than 0.05, 
was used to screen for up-regulation or down-regulation of 
miRNA. The following list represents only a portion of the 
differentially expressed miRNAs in the T to N results (Tab. 4).
Heat map and hierarchical clustering
It was displayed the bidirectional hierarchical clustering 
of samples and miRNAs in the heat map. The abscissa repre-
sented miRNA and the ordinate represented samples. On the 
Table 3. The results of miRNA Expression 
ID Name
Fold Change P-value ForeGround-BackGround Normalized
T vs N T vs N … Mean of N group … Mean of N group
13138 Hy3 0.996336378 0.989417 … 333.4 … 1.148126
42638 hsa-miR-23a-5p 1.568977638 0.07266 … 117.3 … 0.390772
42888 1.14788641 0.665814 … 1586.9 … 5.350498
17519 ebv-miR-BART1-3p 1.097571346 0.730312 … 17.2 … 0.059658
17278 1.160911656 0.5042 … 19.4 … 0.066363
46507 hsa-miR-921 1.586768402 0.200918 … 42.2 … 0.140007
17928 hsa-miR-181a-2-3p 1.510173499 0.312414 … 17.2 … 0.059737
42826 0.783954977 0.240246 … 590.1 … 2.016165
17537 1.008976924 0.970497 … 171.2 … 0.585387
42722 1.739150162 0.078576 … 17 … 0.058376
42645 0.560113342 0.294479 … 22.2 … 0.081096
46636 1.195298862 0.508479 … 31.1 … 0.104871
11134 hsa-miR-502-5p 0.931910856 0.855179 … 252.6 … 0.832847
17295 hsa-miR-583 0.927580386 0.667943 … 503.8 … 1.70745
32825 hsa-miR-620 1.204907579 0.413182 … 40.6 … 0.14099
46276 1.87952483 0.05826 … 6 … 0.021253
ID — Contains the miRNA ID number constituted by Exiqon; Name — miRNA name; P-value — T-test result between samples in different groups; Foldchange — Ratio of 
normalized intensities between two conditions; ForeGround-BackGround — The intensities of the miRNAs before Median normalization; Normalized — The normalized 
values of the miRNAs after Median normalization
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and miRNAs were divided into different groups by cluster 
analysis, which help us to evaluate their correlation.
Hierarchical clustering based on "Differentially ex-
pressed miRNAs in T vs N passed Volcano Plot" was carried 
out. The results of hierarchical clustering showed a distin-
guishable miRNA expression profile between samples. The 
relationship between IGF1 and the expression spectrum of 
miRNA was showed in Figure 3 and Figure 4.
DISCUSSION
The MicroRNA (miRNA) gene is a new class of non- 
-coding single-stranded RNA molecules 19 to 25 nucleotides 
in length that are widely found in eukaryotes and have no 
open reading frame (ORF) [12]. The miRNAs are character-
ized by diversity of species expression, high conservation, 
tissue specificity, and clustering of genes. The miRNAs do not 
directly encode proteins. It is believed that mature miRNAs 
cause complete or incomplete complementary pairing with 
targeted messenger RNAs (mRNAs), causing degradation or 
translational inhibition of target mRNAs and regulating ex-
pression of target genes. More and more researches believe 
Figure 1. The box plots of before and after normalization
Figure 2. Scatter-plot is for Group-T vs Group-N
Before Normalization After Normalization
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Table 4. T vs N 1.5 fold up regulated miRNAs
ID Name
Fold change P-value ForeGround-BackGround Normalized
T vs N T vs N 32 … … 32 … …
148635 hsa-miR-933 1.52065878 0.0283 34 … … 0.103976 … …
168910 hsa-miR-4735-5p 1.63602691 0.029116 52 … … 0.159021 … …
168569 hsa-miR-5088 3.22345834 0.038633 39 … … 0.119266 … …
ID — Contains the miRNA ID number constituted by Exiqon; Name — miRNA name; Foldchange — Ratio of normalized intensities between two conditions; P-value —  
P-value calculated from t-test; ForeGround-BackGround — Intensities of the miRNAs in each sample before Median normalization; Normalized — Normalized values of 
the miRNAs in each sample after Median normalization
left is the miRNA cluster tree, and on the top is the sample 
cluster tree. According to their expression levels, samples 
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that miRNAs play a role in all levels of life. They play an im-
portant role in development, cell differentiation, apoptosis, 
proliferation and tumorigenesis. They have become one of 
the new research hotspots in life sciences in recent years.
The miRNA genes belong to a highly conserved family of 
non-coding genes, and various miRNAs can find homologs 
in other lines [13]. Therefore, miRNAs are involved in various 
important processes in life processes, such as early embry-
Figure 3. Hierarchical clustering for Differentially expressed miRNAs in T vs N passed Volcano Plot. Red indicates high relative expression, and 
green indicates low relative expression
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Figure 4. Signal target network diagram
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onic development, cell differentiation regulation, apoptosis, 
cell cycle, wound healing, and the body's immune system.
The diversity of a miRNA sequence structure and expres-
sion mode plays a very important role in the field of gene 
expression regulation.
Certain miRNAs are abnormally expressed in mouse and 
human placental tissues and are differentially expressed in 
placenta of PE patients. A growing number of studies have 
demonstrated partial differentially expressed miRNAs in the 
placenta of PE patients in cell adhesion, immunity, signal-
ing, and cell cycle cardiovascular development. They play 
an important role in the pathways that play a major role in 
the pathogenesis of pre-eclampsia.
Insulin-like growth factor-1 (IGF-1) is located on the 
short arm of chromosome 12 and contains 70 amino acids 
with a relative molecular mass of 7.6 kD. It is a member 
of the insulin-like growth factor family and has a struc-
ture similar to insulin with insulin-like metabolic effects 
[14]. Most of the IGF-1 in the body's circulation is derived 
from the liver, kidneys, thymus and fat. A small amount of 
IGF-1 can also be detected in tissues. Studies have found 
that IGF-1 can also be produced in the endometrium and 
placenta [15]. In human and animal blood and body fluids, 
IGF-1 rarely exists in a free state, mainly by binding to pro-
teins to form IGF-1 binding protein (IGFBP) to prolong its 
half-life and ensure its stability in vivo.The biological effects 
of IGF-1 are mainly exerted by binding to the IGF-1 receptor 
(IGF-1R), and IGF binding proteins 1 to 6 (IGFBP1 to 6) play 
an important regulatory role in this process. IGF-1 has a wide 
range of biological functions, in addition to promoting in-
sulin metabolism, such as gluconeogenesis and glycolysis, 
hypoglycemic and hypolipidemic. It also has the effects of 
relaxing blood vessels, promoting cell differentiation and 
mitosis.In recent years, its research on the mechanism of 
action in cell differentiation, apoptosis, proliferation and 
carcinogenesis has become a hot topic.
Because IGF-1 may be involved in the regulation of 
embryo implantation, revascularization as well as placen-
tal fetal growth and development. Abnormal expression 
of IGF-1 may lead to pathological pregnancy such as PE, 
which directly affects pregnancy outcomes [16–17]. Studies 
have confirmed that the incidence of PE is associated with 
decreased levels of IGF-1 expression.Some researchers have 
pointed out that the use of immunohistochemistry and 
radioimmunoassay found that IGF-1 levels in peripheral 
blood of patients with preeclampsia decreased compared 
with normal pregnancy While the expression level of IG-
FBP-1 in placenta of preeclampsia increased, presumed 
eclampsia Low levels of IGF-1 in the maternal blood and 
elevated expression of IGFBP-1 in the placenta may lead to 
placental dysplasia and fetal growth restriction. In addition, 
some researchers also compared the expression levels of 
IGF-1 in the pre-eclampsia and normal maternal serum, 
found that the serum levels of IGF-1 in pre-eclampsia were 
significantly lower than those in the control group. There 
was also a significant difference in blood IGF-1 levels be-
tween mild pre-eclampsia and severe pre-eclampsia.The 
more severe the condition, the lower the level of IGF-1 in 
the maternal serum. It was shown that the pre-eclampsia 
condition can be assessed by detecting the expression level 
of IGF-1 in maternal serum [18]. 
CONCLUSIONS
Expression of IGF1 and miRNA was significantly in-
creased in the placentas of patients with preeclampsia. 
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